COMMUNIQUÉS West-GlobeNewswire

Managers’ transactions
18/01/2019
Company announcement no.02/2019 For further information, please contact: Martin Riise, Head of Investor Relations, Tel: +45 53 39 22 50 Camilla Lercke, Head of Media Relations, Tel: +45 53 39 23 84 About Chr. Hansen Chr [...]
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine
18/01/2019
COPENHAGEN, Denmark, January 18, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the [...]
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
18/01/2019
LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug [...]
ERYTECH présente un poster sur l’étude en cours TRYbeCA-1 lors de la conférence annuelle ASCO-GI 2019
18/01/2019
LYON, France et CAMBRIDGE, Mass., 18 janv. 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant [...]
Sunesis Announces Pricing of $20 Million Offering of Securities
18/01/2019
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and ( [...]
Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application
18/01/2019
MORRIS PLAINS, N.J., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today [...]
Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
18/01/2019
FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes PARIS and THE WOODLANDS, TX - January 17, 2019 - The Endocrinologic and Metabolic Drugs Advisory Committee of [...]
Sanofi : Le comité consultatif de la FDA se prononce sur ZynquistaTM (sotagliflozin) dans le traitement du diabète de type 1 de l'adulte
18/01/2019
Le comité consultatif de la FDA se prononce sur Zynquista TM (sotagliflozin) dans le traitement du diabète de type 1 de l'adulte PARIS et THE WOODLANDS (TEXAS) - Le 17 janvier 2019 - Le Comité consultatif des [...]
Lexicon Pharmaceuticals to Host Conference Call and Webcast on January 17, 2019 to Discuss Outcome of FDA Advisory Committee Meeting for Sotagliflozin in Type 1 Diabetes
18/01/2019
THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast on Thursday, January 17, 2019, at 7:00 [...]
FDA Advisory Committee Votes on Zynquista™ (sotagliflozin) as Treatment for Adults With Type 1 Diabetes
18/01/2019
PARIS and THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of [...]
Chembio Diagnostics Announces 2019 Analyst and Investor Meeting
17/01/2019
MEDFORD, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will host an analyst and [...]
Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock
17/01/2019
HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio [...]
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
17/01/2019
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common [...]
Alder BioPharmaceuticals® Appoints Paul Streck, M.D. Chief Medical Officer
17/01/2019
BOTHELL, Wash., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Nextech Named as Finalist in 2019 Stevie® Awards for Sales & Customer Service
17/01/2019
13th annual awards will be presented on February 22 in Las Vegas TAMPA, Fla., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Nextech Systems -- Nextech’s IntelleChartPRO Support Team was named a Finalist today in the Customer [...]
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
17/01/2019
32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patients Well tolerated in dose escalation and expansion cohorts ROCKVILLE, MD, Jan. 17, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX [...]
Major Shareholder Announcement
17/01/2019
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; January 17, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act [...]
Virbac : 2018 annual revenue grew by +4.5% at constant exchange rates
17/01/2019
2018 annual revenue grew by +4.5% at constant exchange rates KEY FIGURES Revenue 2018 Provisional €868.8 million Total growth +0.8% Growth at constant exchange rates +4.5% Growth at constant exchange rates and scope 1 + [...]
Virbac : chiffre d'affaires annuel 2018 en croissance de +4,5% à taux de change constants
17/01/2019
Chiffre d'affaires annuel 2018 en croissance de +4,5% à taux de change constants CHIFFRES CLÉS Chiffre d'affaires 2018 provisoire 868,8 m€ Évolution globale +0,8% Croissance à taux de change constants +4,5% Croissance à [...]

Pages